These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 38086334)
21. Let's turn the CAR-T cells ON and OFF precisely. Zhang J; Du B; Liu M Cancer Cell; 2022 Nov; 40(11):1264-1266. PubMed ID: 36379203 [TBL] [Abstract][Full Text] [Related]
22. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. Han C; Kwon BS Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727 [TBL] [Abstract][Full Text] [Related]
23. Development of Antigen-specific Chimeric Antigen Receptor KHYG-1 Cells for Glioblastoma. Kang CH; Kim Y; Lee SM; Choi SU; Park CH Anticancer Res; 2021 Apr; 41(4):1811-1819. PubMed ID: 33813386 [TBL] [Abstract][Full Text] [Related]
25. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy. Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476 [TBL] [Abstract][Full Text] [Related]
26. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors. Zhang E; Gu J; Xu H Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591 [TBL] [Abstract][Full Text] [Related]
27. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer. Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795 [TBL] [Abstract][Full Text] [Related]
28. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells. Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A Front Immunol; 2018; 9():1717. PubMed ID: 30108584 [TBL] [Abstract][Full Text] [Related]
29. Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma. Zhou S; Sun H; Choi SI; Yin J Front Biosci (Landmark Ed); 2023 Sep; 28(9):206. PubMed ID: 37796692 [TBL] [Abstract][Full Text] [Related]
30. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies. Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A Front Immunol; 2021; 12():665970. PubMed ID: 34475869 [TBL] [Abstract][Full Text] [Related]
31. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026 [TBL] [Abstract][Full Text] [Related]
32. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells. Darowski D; Kobold S; Jost C; Klein C MAbs; 2019; 11(4):621-631. PubMed ID: 30892136 [TBL] [Abstract][Full Text] [Related]
34. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Yu S; Yi M; Qin S; Wu K Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760 [TBL] [Abstract][Full Text] [Related]
35. Identification and targeting of protein tyrosine kinase 7 (PTK7) as an immunotherapy candidate for neuroblastoma. Lee JY; Jonus HC; Sadanand A; Branella GM; Maximov V; Suttapitugsakul S; Schniederjan MJ; Shim J; Ho A; Parwani KK; Fedanov A; Pilgrim AA; Silva JA; Schnepp RW; Doering CB; Wu R; Spencer HT; Goldsmith KC Cell Rep Med; 2023 Jun; 4(6):101091. PubMed ID: 37343516 [TBL] [Abstract][Full Text] [Related]
36. A novel chimeric antigen receptor redirecting T-cell specificity towards CD26 Zhou S; Li W; Xiao Y; Zhu X; Zhong Z; Li Q; Cheng F; Zou P; You Y; Zhu X Leukemia; 2021 Jan; 35(1):119-129. PubMed ID: 32317776 [TBL] [Abstract][Full Text] [Related]
37. A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers. Wei J; Sun H; Zhang A; Wu X; Li Y; Liu J; Duan Y; Xiao F; Wang H; Lv M; Wang L; Wu C Cell Immunol; 2018 Sep; 331():49-58. PubMed ID: 29935762 [TBL] [Abstract][Full Text] [Related]
38. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy. Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403 [TBL] [Abstract][Full Text] [Related]
39. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Kosti P; Maher J; Arnold JN Front Immunol; 2018; 9():1104. PubMed ID: 29872437 [TBL] [Abstract][Full Text] [Related]
40. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer. Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]